APC
RNAM

Aspire Private Capital’s Avidity Biosciences RNAM Stock Holding History

Aspire Private Capital’s Portfolio RNAM Stock Details RNAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-80
Closed -$2K – 663
2021
Q4 		$2K Hold
80
– – ﹤0.01% 539
2021
Q3 		$2K Hold
80
– – ﹤0.01% 502
2021
Q2 		$2K Buy
+80
New +$1.86K ﹤0.01% 501

Other funds holding RNAM

AWA
Aaron Wealth Advisors Chicago, Illinois $1.97B AUM 36.91% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

Aspire Private Capital's RNAM Position: Q1 2022 in Review

Aspire Private Capital sold out of Avidity Biosciences (RNAM) in Q1 2022, closing a stake of 80 shares — an estimated $2K sold.

Aspire Private Capital first reported a position in RNAM in Q2 2021 and held it in 3 quarters. The position peaked at $2K in Q4 2021. 103 funds tracked by Wall St. Rank hold RNAM as of Q1 2022.

  • Aspire Private Capital reported no remaining Avidity Biosciences position as of Q1 2022 after selling out during the quarter.
  • Aspire Private Capital sold 80 Avidity Biosciences shares in Q1 2022, an estimated $2K.
  • Aspire Private Capital first reported a position in Avidity Biosciences in Q2 2021 and held it in 3 quarters.
  • Aspire Private Capital's Avidity Biosciences position peaked at $2K in Q4 2021.
  • 103 funds tracked by Wall St. Rank held Avidity Biosciences as of Q1 2022.

Based on Aspire Private Capital's 13F filing for Q1 2022, filed 10 May 2022.